Tero Aittokallio
PhD
teanai@utu.fi Tykistökatu 6 A Turku ORCID identifier: https://orcid.org/orcid.org/0000-0002-0886-9769 |
Tero Aittokallio received his PhD in Applied Mathematics from the University of Turku in 2001, under the supervision of Prof. Mats Gyllenberg. He then did his post-doctoral training in the Systems Biology Lab at the Institut Pasteur (2006-2007), with Dr. Benno Schwikowski, where he focused on network biology applications using high-throughput experimental assays and network analysis tools such as Cytoscape. In 2007, Dr. Aittokallio launched his independent career as a principal investigator in the Turku Biomathematics Research Group, where he received a five-year appointment as an Academy of Finland Research Fellow (2007-2012). Tero Aittokallio joined Institute for Molecular Medicine Finland (FIMM) as EMBL Group Leader in the fall of 2011, and was selected as Professor of Statistics and Applied Mathematics at University of Turku in 2015.
Aittokallio's research group focuses on developing and applying integrated computational-experimental approaches to tackle biomedical questions, such as how genes function as interaction networks to carry out and regulate cellular processes, how alterations in these networks contribute to complex traits, such as human diseases, and where and how in the disease network one should target to optimally inhibit the disease phenotypes, such as tumor growth.
Computational statistics.
Scientific computing.
- MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth (2015)
- Molecular Oncology
(A1 Refereed original research article in a scientific journal) - Novel therapeutic possibilities for chemorefractory ovarian cancer patients identified by functional ex vivo drug sensitivity testing of primary cells from ascites (2015)
- Cancer Research
(Other publication) - Patient-derived prostate cancer cells for piloting of drug sensitivity and resistance testing (2015)
- BJU International
(Other publication) - Prediction of human population responses to toxic compounds by a collaborative competition (vol 33, pg 933, 2015) (2015)
- Nature Biotechnology
(Other publication) - Pro-apoptotic functions of AMPK revealed by Myc (2015)
- Molecular Cancer Research
(Other publication) - Protein phosphatase 2A activity is a major determinant of therapy response in cancer cells (2015)
- Cancer Research
(Other publication) - Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles (2015)
- Chemistry and Biology
(A1 Refereed original research article in a scientific journal) - TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples (2015)
- Bioinformatics
(A1 Refereed original research article in a scientific journal) - Toward more realistic drug-target interaction predictions (2015)
- Briefings in Bioinformatics
(A1 Refereed original research article in a scientific journal) - What is synergy? The Saariselka agreement revisited (2015)
- Frontiers in Pharmacology
(A2 Refereed review article in a scientific journal )



